 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...2829303132333435363738...100101» |
- letrozole / Generic mfg.
THE RELATIONSHIP BETWEEN THE NUMBER OF MATURE OR STIMULATED FOLLICLES AND MULTIPLE PREGNANCY RATES IN LETROZOLE INTRAUTERINE INSEMINATION (IUI) CYCLES IN WOMEN 18-40 YEARS OF AGE (Anaheim Convention Center - 304AB) - Aug 21, 2022 - Abstract #ASRM2022ASRM_552;
It may not be necessary to cancel women with 3 DF undergoing letrozole IUI as recently recommended by the ASRM for other agents. IMPACT STATEMENT: Letrozole cycles with 3 or less DF should not be cancelled.
- Mifeprex (mifepristone) / Danco Laboratories
EXPLORING THE REPRODUCTIVE BLACK MARKET: FERTILITY MEDICATIONS ON THE DARK WEB (Anaheim Convention Center - 208A) - Aug 21, 2022 - Abstract #ASRM2022ASRM_526;
Due to stigma, drug shortages, and high costs patients will continue to resort to illegal means of obtaining fertility medications despite significant risks of using drugs without a prescription (e.g., counterfeit, contamination, and presence of untested substances). IMPACT STATEMENT: Physicians should be aware of the increasing use of illicit online marketplaces to purchase prescription medications as a significant public health issue (e.g., drug misuse/abuse) as well the risks of serious health consequences including death due to substandard or falsified medical products.
- letrozole / Generic mfg., clomifene citrate / Generic mfg.
THE PREDICTIVE VALUE OF ANTI MULLERIAN HORMONE IN INTRAUTERINE INSEMINATION CYCLES (Anaheim Convention Center - 303CD) - Aug 21, 2022 - Abstract #ASRM2022ASRM_519;
Yet, we demonstrated that there is no difference in ongoing pregnancy rates or clinical pregnancy loss rates among patients with varying levels of AMH in IUI cycles. While AMH is a useful tool to assess ovarian reserve, this study suggests that it should not be over-interpreted as a predictive tool for reproductive potential in IUI cycles.
- | metformin / Generic mfg., letrozole / Generic mfg.
Journal: VNOTES FOR OVARIAN DRILLING: A NEW MINIMAL INVASIVE TECHNIQUE. (Pubmed Central) - Aug 17, 2022
Suture of the posterior vagina Ovarian drilling is a surgical treatment proposed after the failure of first-line treatment in polycystic ovary syndrome to obtain long-term spontaneous ovulations. The development of minimally invasive techniques such as vNOTES will highlight this treatment and allow it to be performed easily and with minimal adverse effects on patients, especially in these bariatric women for whom the vNOTES technique provides easier access to their pelvic cavity than abdominal laparoscopy.
- | Ibrance (palbociclib) / Pfizer
Journal, HEOR, Real-world evidence: Real world evidence study on treatment patterns and health resource utilization in patients with HR+/HER2- locally advanced or metastatic breast cancer in Korea. (Pubmed Central) - Aug 17, 2022
These findings on real world HRU reflected clinical guidelines and severity of ABC. Results can inform future evaluations of new ABC treatments that estimate the health economic impact of their adoption in Korea.
- ||| Reolysin (pelareorep) / Oncolytics, Andrus Reo
Trial termination: AWARE-1: A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (clinicaltrials.gov) - Aug 15, 2022
P1, N=26, Terminated, Sponsor: Oncolytics Biotech
Results can inform future evaluations of new ABC treatments that estimate the health economic impact of their adoption in Korea. Recruiting --> Terminated; Enrollment into AWARE cohorts1-4 have concluded and the primary objective and core goals for the study were met.
- ||| Ibrance (palbociclib) / Pfizer
Biomarker, Trial completion date, Combination therapy, Circulating tumor DNA, Metastases: PADA-1: PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection (clinicaltrials.gov) - Aug 15, 2022
P3, N=1017, Active, not recruiting, Sponsor: UNICANCER
Recruiting --> Terminated; Enrollment into AWARE cohorts1-4 have concluded and the primary objective and core goals for the study were met. Trial completion date: Apr 2024 --> Jun 2025
- | hydrocortisone / Generic mfg., flutamide / Generic mfg.
Trial completion date, Trial primary completion date, Combination therapy: Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Aug 15, 2022
P2, N=62, Active, not recruiting, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Trial completion date: Apr 2024 --> Jun 2025 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- || letrozole / Generic mfg.
Clinical, Journal: Co-treatment of gonadotropin and letrozole in infertile women with endometriosis: A double-blind randomized clinical trial. (Pubmed Central) - Aug 13, 2022
No significant differences were detected between the study groups regarding biochemical or clinical pregnancy (p = 0.72 for both). Letrozole as a co-treatment drug in the IVF cycle of women with endometriosis can significantly reduce the gonadotropin dosage and estradiol level with the same pregnancy rates.
- Panel Participant (118C) - Aug 11, 2022 - Abstract #AHA2022AHA_2666;
Letrozole as a co-treatment drug in the IVF cycle of women with endometriosis can significantly reduce the gonadotropin dosage and estradiol level with the same pregnancy rates. There is no abstract associated with this presentation.
- || Bizengri (zenocutuzumab-zbco) / Merus, Partner Therap
Trial completion date, Trial primary completion date: MCLA-128-CL02: MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer. (clinicaltrials.gov) - Aug 11, 2022
P2, N=101, Active, not recruiting, Sponsor: Merus N.V.
There is no abstract associated with this presentation. Trial completion date: Dec 2022 --> Feb 2024 | Trial primary completion date: Dec 2021 --> Dec 2023
- | Ibrance (palbociclib) / Pfizer
Journal, Real-world evidence: Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2- Breast Cancer at a Single Cancer Center. (Pubmed Central) - Aug 11, 2022
A number of clinical and demographic features were associated with PFS on CDK4/6 inhibitor-based therapy. Further studies are ongoing to validate these findings incorporating additional cancer centers.
- ||| Verzenio (abemaciclib) / Eli Lilly
Trial completion date, Metastases: MONARCH plus: A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer (clinicaltrials.gov) - Aug 10, 2022
P3, N=463, Active, not recruiting, Sponsor: Eli Lilly and Company
Further studies are ongoing to validate these findings incorporating additional cancer centers. Trial completion date: Feb 2023 --> Sep 2023
- | letrozole / Generic mfg., clomifene citrate / Generic mfg.
Journal: The Effect of Clomiphene Citrate and Letrozole in Apoptotic Pathways and Cell Cycle in Human Primary Cumulus Cells and the Protective Effect of Estradiol. (Pubmed Central) - Aug 10, 2022
These findings suggest that clomiphene citrate and letrozole do not significantly affect the viability of human cumulus cells. Still, the expression of genes involved in apoptosis was modulated by these drugs alone and in association with estradiol, suggesting that CC and letrozole may have direct effects on cumulus cells beyond their known mechanisms of action.
- letrozole / Generic mfg.
Coordination of CO2 adsorption capacity and metal electron cloud density to facilitate hydrogenation of CO2 to formate (Virtual-only (Zoom)) - Aug 9, 2022 - Abstract #ACSFall2022ACS_Fall_11086;
At the same time, formic acid is a good hydrogen (H2) storage material with good application prospects.A novel covalent triazine framework CTF-L formed by the polymerization of letrozole was successfully synthesized through ionothermal method...The balance between the two can be harmonized to achieve the best activity of the catalyst.The best catalyst efficiently converted CO2 into formate through hydrogenation with a turnover number of 22000 after 1 h, being the highest reported to date for a heterogeneous catalyst, which makes it attractive toward industrial application. Furthermore, the synthesized catalyst was found to be stable in air and was recycled by simple filtration without significant loss of catalytic activity.
- | letrozole / Generic mfg., fluvastatin / Generic mfg., clopidogrel / Generic mfg.
Pricing, Journal, HEOR, Real-world evidence: The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing Data. (Pubmed Central) - Aug 7, 2022
Assuming dynamic drug prices may lead to more representative ICER estimates. Future CEAs for drugs could account for predicted and disaggregated life cycle price developments based on retrospective data.
- | letrozole / Generic mfg.
Journal: The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer. (Pubmed Central) - Aug 7, 2022
Larger adipocyte diameter was identified as predictor of anti-proliferative response (OR per increase in diameter of 5 μm for adipocytes distant from the tumor: 2.24, 95%CI: 1.01-14.32, p = 0.046). This study suggests that anti-proliferative response to neoadjuvant letrozole might be more frequent in patients with increased systemic or mammary adiposity.
- | metformin / Generic mfg., letrozole / Generic mfg.
Preclinical, Journal: The Improvement Effect of D-Chiro-Inositol and Ecklonia cava K. in the Rat Model of Polycystic Ovarian Syndrome. (Pubmed Central) - Aug 7, 2022
In rats with letrozole-induced PCOS, we focused on alternative therapies using EC and/or DCI extracts to alleviate ovarian failure...We divided 6-week-old female mice into the following six groups and evaluated them: vehicle, PCOS, PCOS + MET (metformin), PCOS + DCI, PCOS + EC, and PCOS + DCI + EC...These treatments also appeared to regulate the production of factors that affect follicle formation and inflammation in the ovaries. We concluded that EC extract and/or DCI administration influenced aromatase production and reduced LH and T stimulation, and cotreatment with EC and DCI consequently restored ovarian dysfunction or anti-inflammatory responses in rats with PCOS-like symptoms.
- | letrozole / Generic mfg.
Preclinical, Journal: Effect of Aloe vera (Barbadensis Mill) on Letrozole Induced Polycystic Ovarian Syndrome in Swiss Albino Mice. (Pubmed Central) - Aug 6, 2022
After the treatment of Aloe vera and Diane, all the parameters showed considerable good results. The findings of the current study provide a baseline data for designing further investigations on the therapeutic benefits of Aloe vera as an adjunct therapy in the management of PCOS.
- ||| letrozole / Generic mfg.
P3 data, Journal: Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial. (Pubmed Central) - Aug 6, 2022
P=N/A
Large breast size was a risk factor for radiation-associated induration. Few recurrences were detected and unrelated to PBI.
- | Ibrance (palbociclib) / Pfizer
Trial completion date, Trial initiation date, Trial primary completion date, Liquid biopsy, Metastases, Biopsy: ICRG0201: Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies. (clinicaltrials.gov) - Aug 4, 2022
P2, N=80, Not yet recruiting, Sponsor: International Cancer Research Group, United Arab Emirates
Few recurrences were detected and unrelated to PBI. Trial completion date: Dec 2025 --> Apr 2026 | Initiation date: Jan 2022 --> Sep 2022 | Trial primary completion date: Dec 2022 --> Apr 2023
- | letrozole / Generic mfg.
Trial completion date, Trial primary completion date: Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE) (clinicaltrials.gov) - Aug 4, 2022
P4, N=565, Recruiting, Sponsor: Erasme University Hospital
Trial completion date: Dec 2025 --> Apr 2026 | Initiation date: Jan 2022 --> Sep 2022 | Trial primary completion date: Dec 2022 --> Apr 2023 Trial completion date: Jan 2027 --> Jan 2029 | Trial primary completion date: Jan 2022 --> Dec 2023
- | letrozole / Generic mfg.
New trial: Letrozole in Preventing Recurrence of Endometrioma Following Laparoscopic Ovarian Cystectomy (clinicaltrials.gov) - Aug 4, 2022
P=N/A, N=194, Not yet recruiting, Sponsor: The University of Hong Kong
- | letrozole / Generic mfg.
Enrollment open: Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer (clinicaltrials.gov) - Aug 4, 2022
P2, N=50, Recruiting, Sponsor: Mayo Clinic
Trial completion date: Jan 2027 --> Jan 2029 | Trial primary completion date: Jan 2022 --> Dec 2023 Not yet recruiting --> Recruiting
- ||| Avastin (bevacizumab) / Roche
Trial completion, Metastases: BOOSTER: Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer (clinicaltrials.gov) - Aug 4, 2022
P2, N=160, Completed, Sponsor: Japan Breast Cancer Research Group
Not yet recruiting --> Recruiting Unknown status --> Completed
- | Rekovelle (follitropin delta) / Ferring
Journal: Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols. (Pubmed Central) - Aug 4, 2022
Our study showed that adding tamoxifen or letrozole to a standard ovarian stimulation protocol in women with breast cancer does not impact the effectiveness of fertility preservation and paves the way for high-quality long-term follow-up on breast cancer treatment outcomes and women's future pregnancy outcomes. Our study also highlights the need for high-quality studies for all women opting for fertility preservation, as alternative ovarian stimulation protocols have been introduced to clinical practice without proper evidence.
- | letrozole / Generic mfg.
Trial completion date: Brovale: Fertility Preservation in Breast Cancer Patients (clinicaltrials.gov) - Aug 3, 2022
P4, N=65, Active, not recruiting, Sponsor: Erasme University Hospital
Our study also highlights the need for high-quality studies for all women opting for fertility preservation, as alternative ovarian stimulation protocols have been introduced to clinical practice without proper evidence. Trial completion date: Dec 2022 --> Sep 2023
- | letrozole / Generic mfg.
Journal: Long-Term Treatment With Letrozole in a Boy With Familial Male-Limited Precocious Puberty. (Pubmed Central) - Aug 3, 2022
A patrilineal mutation of the LHCGR gene has been identified in a boy with FMPP. His height is 168.7cm (-0.05SD) which is approaching his adult height after long-term treatment with letrozole, triptorelin, and spironolactone.
- | letrozole / Generic mfg.
Preclinical, Journal: Short chain fatty acid, acetate restores ovarian function in experimentally induced PCOS rat model. (Pubmed Central) - Aug 3, 2022
His height is 168.7cm (-0.05SD) which is approaching his adult height after long-term treatment with letrozole, triptorelin, and spironolactone. Altogether, the present results suggest that acetate protects ovarian function with evidence of normal growing follicles and enhanced circulating 17-β estradiol by inhibition of HDAC.
- | Phase classification, Enrollment change, Trial completion date, Trial primary completion date: STAPOVER: Signal TrAnsduction Pathway Activity Analysis in OVarian cancER (clinicaltrials.gov) - Aug 2, 2022
P2/3, N=148, Not yet recruiting, Sponsor: Gynaecologisch Oncologisch Centrum Zuid
Altogether, the present results suggest that acetate protects ovarian function with evidence of normal growing follicles and enhanced circulating 17-β estradiol by inhibition of HDAC. Phase classification: P3 --> P2/3 | N=50 --> 148 | Trial completion date: Dec 2023 --> Oct 2026 | Trial primary completion date: Aug 2023 --> Oct 2025
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Enrollment closed: MUKDEN 01: Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial (clinicaltrials.gov) - Aug 2, 2022
P2, N=89, Active, not recruiting, Sponsor: Shengjing Hospital
Phase classification: P3 --> P2/3 | N=50 --> 148 | Trial completion date: Dec 2023 --> Oct 2026 | Trial primary completion date: Aug 2023 --> Oct 2025 Recruiting --> Active, not recruiting
- | letrozole / Generic mfg.
Journal: Letrozole induced visual hallucination. (Pubmed Central) - Jul 31, 2022
Recruiting --> Active, not recruiting No abstract available
- | metformin / Generic mfg.
Preclinical, Journal: Metformin ameliorates polycystic ovary syndrome in a rat model by decreasing excessive autophagy in ovarian granulosa cells via the PI3K/AKT/mTOR pathway. (Pubmed Central) - Jul 31, 2022
We demonstrated that metformin ameliorated PCOS in a rat model by downregulating autophagy in GCs, and metformin decreased the levels of oxidative stress and autophagy in HO-induced GCs and affected the PI3K/AKT/mTOR signaling pathway. Taken together, our results indicate that metformin ameliorates PCOS in a rat model by decreasing excessive autophagy in GCs via the PI3K/AKT/mTOR pathway, and this study provides evidence for targeted reduction of excessive autophagy of ovarian granulosa cells and improvement of PCOS.
- | letrozole / Generic mfg., anastrozole / Generic mfg.
Journal: Androstenedione and Follicle-Stimulating Hormone Concentration Predict the Progression of Frailty Syndrome at One Year Follow-Up in Patients with Localized Breast Cancer Treated with Aromatase Inhibitors. (Pubmed Central) - Jul 29, 2022
Taken together, our results indicate that metformin ameliorates PCOS in a rat model by decreasing excessive autophagy in GCs via the PI3K/AKT/mTOR pathway, and this study provides evidence for targeted reduction of excessive autophagy of ovarian granulosa cells and improvement of PCOS. Hormonal concentrations before AROi treatment constitute possible biomarkers to predict the progression of frailty syndrome.
- | letrozole / Generic mfg.
Preclinical, Journal: Effect of Letrozole Administration as a Selective Aromatase Inhibitor on Male Rat's Reproductive Performance. (Pubmed Central) - Jul 29, 2022
In the T3 group, there was no significant atrophy or other pathology. The results of the current study suggested that letrozole improved spermatogenesis while causing no visible pathological alterations in testis tissue.
- Kisqali (ribociclib) / Novartis
Single cell characterization of longitudinal biopsies from breast cancer patients treated with the aromatase inhibitor letrozole and the CDK4/6 inhibitor ribociclib (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_3366;
We also compare our annotations with publish methods identifying cell states in single cell data (Luca et al., Cell 2021). Conclusions We highlight how scRNA-seq and our analytic pipelines are allowing us to study the tumor microenvironment of breast cancer biopsies at a very high resolution.
- Ibrance (palbociclib) / Pfizer
Patient-reported quality of life in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer (ABC) treated with palbociclib (PAL) plus letrozole (LET): Results from PALOMA-4 (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2949;
P3
Conclusions The PROs demonstrate that quality of life is maintained in treatment-naive, postmenopausal Asian women with HR+/HER2– ABC treated with PAL + LET. Findings are consistent with PROs in the PALOMA-2 cohort and support the use of PAL as first-line treatment in Asian patients with HR+/HER2– ABC.
- Piqray (alpelisib) / Novartis
BYLieve trial (alpelisib [ALP] + endocrine therapy [ET]) versus real-world (RW) standard of care (SOC) in patients (Pts) with PIK3CA-mutated (Mut), hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) who progressed on cyclin-dependent kinase 4/6 inhibitor (CDKi) therapy (Tx) (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2417;
P2
Planned analyses will compare rwPFS by median treatment duration (mTD) on prior CDKi in RW cohorts (SOC minus ALP) with BYLieve Cohorts A and B. Methods BYLieve Cohorts A (ALP + FUL) and B (ALP + letrozole [LET]) and RW cohorts were retrospectively analyzed...Matched BYLieve PFS data by mTD and descriptive biomarker data will be presented. Table: 222P conclusions Matched-cohort analyses will elucidate the clinical benefit of ALP + ET vs SOC for RRP/RP pts with PIK3CA-mut, HR+, HER2– ABC who progressed on CDKi.
- Kisqali (ribociclib) / Novartis
Pooled exploratory analysis of survival in patients (pts) with HR+/HER2- advanced breast cancer (ABC) and visceral metastases (mets) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA (ML) trials (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2309;
P3
In ML-7, premenopausal pts were randomized 1:1 to receive 1L RIB or PBO and goserelin with nonsteroidal aromatase inhibitor (NSAI)/tamoxifen (only pts in the NSAI arm were included in this analysis)...This analysis also demonstrates the substantial benefit of RIB in those with poorer outcomes within the visceral mets subgroup, ie, pts with liver mets and those with multiple met disease sites, especially in the 1L population. Table: 205P
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
The impact of body mass index (BMI) on the progression-free survival of CDK4/6 inhibitors in metastatic breast cancer patients (MBC) (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2232;
Conclusions In this study, we demonstrated that the overweight patients with MBC may benefit more from CDK4/6 inhibitors in term of PFS. Similar toxicity rates were observed in all BMI groups with CDK4/6 inhibitors plus ET.
- Kisqali (ribociclib) / Novartis
SOLTI-1911: Neoadjuvant and adjuvant ribociclib and endocrine therapy for clinically high-risk estrogen receptor-positive and HER2-negative breast cancer (RIBOLARIS) (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_1945;
P2
Two interim analysis are planned. Recruitment (53 sites in Spain, France and Portugal) started in April 2022.
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
HARMONIA SOLTI-2101 / AFT-58: A head-to-head phase III study comparing ribociclib (RIB) and palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC) (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_1912;
P3
In the basal-like cohort, pts will be treated with paclitaxel...Primary EP final analysis will be performed after 310 PFS events are observed (∼80% power using one-sided 5% α). HARMONIA will recruit in Spain (40 sites), Portugal (5), and US (35) within SOLTI & AFT network.
- || Kisqali (ribociclib) / Novartis
Trial primary completion date, Combination therapy, Metastases: FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer (clinicaltrials.gov) - Jul 28, 2022
P2, N=194, Recruiting, Sponsor: Fondazione Sandro Pitigliani
HARMONIA will recruit in Spain (40 sites), Portugal (5), and US (35) within SOLTI & AFT network. Trial primary completion date: Jun 2022 --> Dec 2022
- |||| Herceptin (trastuzumab) / Roche, Kisqali (ribociclib) / Novartis, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date: Detect V / CHEVENDO (Chemo vs. Endo) (clinicaltrials.gov) - Jul 28, 2022
P3, N=270, Recruiting, Sponsor: Prof. W. Janni
Trial primary completion date: Jun 2022 --> Dec 2022 Trial completion date: Jun 2023 --> Nov 2024 | Trial primary completion date: Sep 2021 --> Sep 2024
- | letrozole / Generic mfg.
Preclinical, Journal: Distinctions in PCOS induced by letrozole versus dehydroepiandrosterone with high-fat diet in mouse model. (Pubmed Central) - Jul 28, 2022
In comparison, normal diet and/or letrozole produced fewer features of PCOS. The data from the experimental models presented here can improve our understanding of growing concern over women's health caused by PCOS.
- Keytruda (pembrolizumab) / Merck (MSD)
Debate Your Colleague 02: Optimal Treatment of Recurrent Low Grade Endometrial Cancer (Hall 501) - Jul 27, 2022 - Abstract #IGCS2022IGCS_339;
Different approaches to treatment including chemotherapy, checkpoint inhibitor therapy, and combination therapy with pembrolizumab and lenvatanib will be discussed. The role of hormonal therapies (i.e.megesterol acetate, letrozole, etc) and hormonal combination therapies in the treatment of low grade endometrial cancer will be highlighted.
- | 5-fluorouracil / Generic mfg., letrozole / Generic mfg., exemestane / Generic mfg.
Journal: Ursolic acid silences CYP19A1/aromatase to suppress gastric cancer growth. (Pubmed Central) - Jul 27, 2022
The docking simulation score of UA was compared with Ar inhibitors, e.g., letrozole, exemestane, in Ar protein crystallization...Together, the results indicate UA could be used to treat GCa by silencing Ar expression in GCa. Hedyotis diffusa Willd ethanol extract could be an functional food supplements.
- | Mifeprex (mifepristone) / Danco Laboratories
Enrollment open: Comparison Between Letrozole and Mifepristone in Medical Termination of First Trimester Miscarriages (clinicaltrials.gov) - Jul 26, 2022
P3, N=120, Recruiting, Sponsor: Calcutta National Medical College and Hospital
Hedyotis diffusa Willd ethanol extract could be an functional food supplements. Not yet recruiting --> Recruiting
- ||| Kisqali (ribociclib) / Novartis
Enrollment open: Roll-over Study to Allow Continued Access to Ribociclib (clinicaltrials.gov) - Jul 26, 2022
P4, N=137, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
HER2DX genomic test in HER2-positive/hormone receptor-positive (HER2+/HR+) breast cancer (BC) treated with neoadjuvant trastuzumab (T) and pertuzumab (P): A correlative analysis from the PerELISA trial (7.1.C - Cannes Auditorium) - Jul 25, 2022 - Abstract #ESMO2022ESMO_1477;
Conclusions HER2DX predicts endocrine sensitivity and pCR following neoadjuvant T+P+letrozole in pts with early-stage HER2+/HR+ BC. HER2DX could help tailor systemic therapy in this context.